Curis cancer drug put on partial hold after patient death

(Reuters) - Curis Inc said it had been stopped from enrolling any new patients in an early stage trial of its experimental cancer drug following the death of a patient who had liver failure. Curis's shares fell 10 percent in premarket trading after the U.S. Food and Drug Administration placed a partial hold on the trial. Curis said it expects to respond to the agency's requests in a timely manner. One patient with advanced breast cancer developed what the company said were "serious adverse events" related to liver function.



via Health News Headlines - Yahoo! News http://news.yahoo.com/curis-cancer-drug-put-partial-hold-patient-death-125440148--sector.html